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ZD6474 selectively targets two key pathways in tumour growth by inhibiting vascular endothelial growth factor (VEGF)-dependent
tumour angiogenesis and epidermal growth factor (EGF)-dependent tumour cell proliferation and survival. Phase I clinical evaluation
has shown ZD6474 to be generally well tolerated, with a pharmacokinetic profile appropriate for once-daily oral dosing. Phase II
evaluation of ZD6474 at doses of 100 300mg is ongoing in a range of patient types in single and combination regimens. These
include three randomised studies of patients with non-small-cell lung cancer. In one of these trials, the efficacy of ZD6474
monotherapy is being compared with that of the EGF receptor tyrosine kinase inhibitor gefitinib (Iressat) in previously treated
patients. In the other two trials, the efficacy of ZD6474 in combination with certain standard chemotherapy regimens is being
compared with that of standard chemotherapy alone: one with carboplatin and paclitaxel in previously untreated patients, and the
second with docetaxel in patients who progressed after platinum-containing therapy. The advent of novel molecular-targeted agents
such as ZD6474 has necessitated a re-evaluation of conventional cancer study design in order to optimise appraisal of this new
generation of anticancer agents. The specific considerations of the ZD6474 clinical programme are discussed.
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It is generally accepted that significant advances in cancer
treatment will require the identification of novel targets critical
for cancer growth and progression, and the development of
strategies to inhibit these targets. Two promising targets are the
vascular endothelial growth factor (VEGF) pathway, which is a key
mediator of tumour angiogenesis, and the epidermal growth factor
receptor (EGFR). The therapeutic value of inhibiting these targets
has been demonstrated by the anti-VEGF monoclonal antibody,
bevacizumab (Avastint), the anti-EGFR monoclonal antibody
cetuximab (Erbituxt) and the EGFR tyrosine kinase inhibitors
erlotinib (Tarcevat) and gefitinib (Iressat) (Fukuoka et al, 2003;
Cunningham et al, 2004; Hurwitz et al, 2004; Shepherd et al, 2004).
ZD6474 is an oral, small molecule inhibitor of VEGFR and EGFR
tyrosine kinase activity. By targeting these two pathways, ZD6474
has the potential to offer the combined benefits of directly
inhibiting tumour cell proliferation and survival like other EGFR
inhibitors, as well as inhibiting tumour angiogenesis by inhibiting
VEGF activity. In addition, EGFR inhibitors have themselves been
shown to exert antiangiogenic effects by reducing the expression
of VEGF and other angiogenic factors by tumours (Ciardiello et al,
2001), and inhibiting EGFR on tumour endothelium (Bruns et al,
2000; Baker et al, 2002). Combined blockade of the VEGF and
EGFR pathways may therefore provide greater benefit than
blockade of either pathway alone. Although clinical experience
with combined VEGF/EGFR inhibition is limited, in a recent phase
I/II trial of patients with previously treated non-small-cell lung
cancer (NSCLC; nonsquamous histology) the combination of
erlotinib and bevacizumab showed encouraging antitumour
activity (Herbst et al, 2005).
ZD6474 CLINICAL EVALUATION: CONSIDERATIONS
IN TRIAL DESIGN
Clinical evaluation of the new generation of molecular-targeted
therapies has presented a number of challenges, not least of which
is how to design clinical trials that effectively identify the potential
of these novel agents. The format of a typical cancer study has
developed over many years to evaluate cytotoxic chemotherapy
regimens, where tumour regression is the expected outcome for an
active agent. In contrast, antiangiogenic agents, like many other
types of targeted drugs, are more likely to elicit a cytostatic effect,
rather than tumour shrinkage. In addition, while cytotoxic agents
are typically used at doses at or near the maximum tolerated dose
(MTD), the optimal dose for targeted agents may be at doses far
below the MTD. Evaluation of these agents will therefore require
refinements in trial design to robustly detect ‘soft’ end points such
as stable disease, coupled with the development and validation of
improved markers for assessing biological activity.
The principal objective of initial clinical evaluation of ZD6474
was to determine safety and tolerability of this agent, and is
discussed below. This followed a conventional format and, as
is typical for phase I testing, involved patients with advanced,
refractory tumours of various types. The inclusion of a 7-day
observation period following initial dosing in these studies also
enabled assessment of both single- and multiple-dose effects
within the same study. Evidence of tumour responses to ZD6474
therapy seen in the phase I programme and the known activity
of EGFR inhibitors in NSCLC prompted a comprehensive phase II
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evaluation of ZD6474 in NSCLC is the assessment of time-to-
tumour progression, which is considered the best description of
clinical effect of the antiangiogenic agents. Assessment of tumour
response is also included as a secondary end point to capture any
frank responses to therapy.
Although phase II studies tend not to include a control arm and
aim to enrol the minimum number of patients, the use of
randomised trials has recently been recommended for screening
promising new agents, especially those expected to be cytostatic
(Korn et al, 2001; Simon et al, 2001). In such trials, a one-sided
P-value of less than 0.2 is considered evidence that the new agent
shows sufficient promise to warrant further investigation, that is,
a P-value of o0.2 would indicate that there was a less than 1 in 5
probability that the observed increase in activity was due to chance
alone. A randomised trial design has been adopted for the phase II
evaluation of ZD6474 in NSCLC in order to provide more
meaningful outcomes than single-arm studies and avoid the
necessity for comparison with historical data. The combination
studies include a safety run-in phase designed to evaluate the
tolerability profile of the combination and to allow early
identification of any pharmacokinetic interactions prior to the
main randomised phase. Collection of a wealth of additional data
is also included in these protocols, including health-related quality
of life assessments using the Functional Assessment of Cancer
Therapy-Lung (FACT-L) questionnaire and lung cancer subscore.
This will provide useful information for determining appropriate
outcome end points for future studies.
PHASE I CLINICAL EVALUATION
ZD6474 has been evaluated in two phase I clinical trials of patients
with advanced solid tumours refractory to standard therapy
(Figure 1). The primary objective of both studies was to evaluate
the safety and tolerability of ascending doses of ZD6474. Secondary
objectives included assessment of the pharmacokinetic profile of
ZD6474, determination of the MTD and preliminary assessment of
ZD6474 antitumour activity.
Study A recruited 77 patients from five sites in the USA and
Australia (Hurwitz et al, 2002). Patients with a variety of solid
tumours were included, most having colorectal cancer (CRC)
(n¼23), but only one had NSCLC. Patients received daily oral
ZD6474 at doses of 50, 100, 200, 300, 500 or 600mg in 28-day
cycles. Preliminary data from 49 patients shows that good
tolerability at doses as high as 500mg and dosing for 4100 days
has been achieved. Expanded cohorts of 8–10 patients were also
evaluated sequentially at 100 and 300mg dose levels in order to
further characterise the safety, tolerability and biological activity of
ZD6474. The incidence of rash and diarrhoea appeared to be dose-
related and asymptomatic QTc prolongation was observed in seven
patients at varying dose levels. The observation of three CTC grade
3 events in patients receiving 600mg ZD6474 (two episodes of
diarrhoea and one of thrombocytopenia) indicated that this dose
level exceeded the MTD and no further dose escalation was
performed. ZD6474 exposure (Cmax, AUC) following single-dose
administration increased with dose. The t1/2 was long (4100h)
and did not change with increasing dose. The anti-VEGF activity of
ZD6474 was suggested by the occurrence of hypertension and
delayed dermal wound angiogenesis, although no tumour
responses were seen in this study.
Study B recruited 18 patients in Japan, most of whom had
NSCLC or CRC (n¼9 and 4, respectively). Patients received
ZD6474 at doses of 100, 200, 300 or 400mg in 28-day cycles. In this
study, ZD6474 therapy was well tolerated at doses of up to
300mgday
 1, the most common adverse events being rash,
asymptomatic QTc prolongation, diarrhoea, proteinuria and
hypertension. Two patients developed a DLT (grade 3 ALT
elevation and grade 3 hypertension) at 400mgday
 1, which was
considered to exceed the MTD. According to RECIST criteria, four
of the nine patients with NSCLC exhibited an objective response to
ZD6474 therapy. Two of the observed tumour responses are shown
in Figure 2, both patients received dose reductions (300–200 and
200–100mgday
 1) following an adverse event. It is not known
whether these patients had EGFR mutations characteristic of
NSCLC patients that are highly responsive to EGFR inhibitors
(Lynch et al, 2004; Paez et al, 2004). In preclinical studies, EGFR
mutations known to increase the sensitivity of EGFR to gefitinib
and erlotinib also increased sensitivity to ZD6474 (Arao et al, 2004;
Briggs et al, 2005).
In summary, phase I evaluation of ZD6474 has shown this novel
agent to be well tolerated at daily oral doses of p300mg. Observed
adverse events were generally mild and readily controlled with
dose adjustment or appropriate therapy; all QTc prolongation
events were asymptomatic. The pharmacokinetic profile of ZD6474
was compatible with once-daily oral dosing and did not differ
between the Western and Japanese studies. This, along with the
encouraging tumour response data, has prompted initiation of a
comprehensive series of phase II clinical evaluations.
PHASE II CLINICAL EVALUATION OF ZD6474
Phase II assessment of ZD6474 is now underway in a variety of
tumour types in single and combination regimens. ZD6474 doses
of 100 300mgday
 1 were selected for the phase II studies, as
these doses are known to be well tolerated and pharmacokinetic
data from phase I evaluation indicate that even the 100mg dose is
expected to yield biologically active systemic concentrations of
ZD6474.
Single dose
PD 
or 
DLT
Cycle 0 
(7 days)
Cycle 1  
(28 days)
Cycle 2 
(28 days)
Further  
28-day cycles 
7-day 
observation 
period
PD=progressive disease; DLT=dose-limiting toxicity
Figure 1 Phase I study design. ZD6474 dosed once-daily p.o. Study A 50–600mg; study B 100–400mg.
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Although the activity of ZD6474 is being assessed in a range of
tumour types, the responses to ZD6474 in patients with NSCLC
seen in phase I study B have prompted a series of studies in this
tumour type. Current standard therapy for NSCLC has only
limited efficacy and although a minority of patients do respond
to treatment, the majority of responders will eventually develop
progressive disease (Schiller et al, 2002). The prognosis for
patients with this tumour type therefore remains poor and there
is a high unmet need for new therapies.
As with all solid tumours, the role of angiogenesis is well
established in the progression of lung cancers, and high
microvessel density has been shown to be predictive of tumour
progression, metastasis and therefore poor prognosis (Macchiarini
et al, 1992, 1994; Fontanini et al, 1997; Lucchi et al, 1997; Meert
et al, 2002). It is therefore possible that inhibition of VEGF activity
and thereby angiogenesis could have significant therapeutic
benefits in patients with NSCLC.
ZD6474 VS GEFITINIB IN PREVIOUSLY TREATED
NSCLC
Gefitinib is a small molecule inhibitor of the EGFR tyrosine kinase
that has demonstrated significant antitumour efficacy in patients
with previously treated NSCLC (Fukuoka et al, 2003). In order
to determine the additional benefit of VEGFR tyrosine kinase
inhibition, a comparative study of ZD6474 and gefitinib has been
initiated in subjects with locally advanced or metastatic (IIIB/IV)
NSCLC after failure of either first-line and/or second-line
platinum-based chemotherapy. The crossover design (Figure 3)
also allows assessment of the activity of ZD6474 in subjects who
have failed treatment with gefitinib. In part A, patients receive
daily oral doses of either ZD6474 300mg or gefitinib 250mg. The
ZD6474 dose selection was based on extrapolations from in vitro
studies, which demonstrated that the 300mg dose of ZD6474 could
be expected to provide approximately equivalent inhibition of the
EGFR tyrosine kinase as gefitinib 250mg. Treatment continues
until withdrawal due to disease progression, toxicity or removal of
informed consent. After a washout period of 4 weeks, patients are
switched to the alternative treatment (part B), which continues
until a withdrawal criterion is reached. In both parts of this study,
the dual primary objective is evaluation of time to progression and
assessment of safety/tolerability. The initial phase of this study is
now complete and the results are anticipated shortly.
ZD6474 PLUS DOCETAXEL
Docetaxel is currently a standard chemotherapy agent for
previously treated patients with NSCLC. In randomised phase III
studies, the overall response rate has ranged from 6 to 9%, with
a median progression-free survival of 8.5 12.6 weeks (Shepherd
et al, 2000; Fossella et al, 2000; Hanna et al, 2004). Docetaxel has
also been found to act synergistically with VEGF pathway
inhibitors in preclinical studies (Sweeney et al, 2001).
The potential for improved therapeutic efficacy in combination
with ZD6474 is being investigated in a two-part randomised,
double-blind, placebo-controlled trial (Figure 4). Patients with
locally advanced or metastatic NSCLC after failure of first-line
platinum-based chemotherapy were recruited and initially received
docetaxel (75mgm
 2 i.v. infusion every 21 days) plus daily oral
ZD6474 (100 or 300mg) in the open-label safety run-in phase. In
the subsequent randomised phase, a docetaxel/placebo group was
included. The primary objective of this study is to compare
progression-free survival, as determined by objective tumour
assessments (revised RECIST).
A randomised study, rather than a single-arm protocol, was
performed as the activity of docetaxel observed to date in second-
line NSCLC trials has been highly variable, making comparison
Predose Withdrawal (cycle 5, day 9)
Predose Withdrawal (cycle 7, day 29)
A
B
Figure 2 Tumour responses observed in phase I study of ZD6474. (A) Female, 50years, receiving ZD6474 300-200mgday
 1;( B) male, 72years,
receiving ZD6474 200-100mgday
 1.
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arm allows the tolerability profile of the combination arms to be
rigorously placed into context with that observed for docetaxel
alone.
Preliminary data from the run-in phase of this study have
demonstrated that the combination of ZD6474 and docetaxel does
not significantly increase the toxicity or exposure of either agent
(Heymach et al, 2004). The combination was generally well
tolerated and adverse events were manageable. Approximately half
of the patients exhibited stable disease X12 weeks and two partial
responses were seen in the ZD6474 300mg cohort (Figure 5).
Overall median time to disease progression was 15.1 and 19.8
weeks in the ZD6474 100 and 300mg cohorts, respectively. There
was a higher incidence of rash in the 300mg cohort, possibly due
in part to a higher degree of EGFR inhibition. These data therefore
support progression to the double-blind, randomised phase, which
has now completed accrual.
ZD6474 PLUS CARBOPLATIN AND PACLITAXEL
ZD6474 is being evaluated in an ongoing randomised, double-
blind phase II study, alone and in combination with carboplatin/
paclitaxel (CP), as first-line treatment for patients with locally
advanced or metastatic (IIIB-IV) NSCLC (Figure 6). A safety run-
in phase was conducted to establish the appropriate dose of
ZD6474 to be administered in combination with CP, and
comprised 21-day treatment cycles in which 10 subjects per
cohort received daily oral doses of ZD6474 (1st cohort, 200mg;
2nd cohort, 300mg) in combination with CP (carboplatin, target
AUCss¼6mgml
 1min; paclitaxel, 200mgm
 2 i.v.). In the rando-
mised phase, the inclusion of a control arm will allow the
tolerability profile of the ZD6474/CP combination arm to
accurately compare with that of CP only.
Preliminary data from the run-in phase of this study show that
the ZD6474/CP combination is generally well tolerated (Johnson
et al, 2005). Partial responses have been observed in seven out of
18 patients and stable disease X12 weeks in a further two patients.
Preliminary pharmacokinetic data indicate that mean steady-state
plasma levels of ZD6474 after 200mg dosing are comparable when
given alone (684ngml
 17272) or in combination with CP
(568ngml
 17206). These preliminary results have supported
progression to the randomised phase, which is currently ongoing.
It is worth noting that two previous phase III studies of CP
combined with either gefitinib or erlotinib did not demonstrate
improved survival compared with CP alone (Herbst et al, 2004a,b).
When CP was combined with the VEGF inhibitor bevacizumab,
however, promising activity was seen in terms of overall response
rate and time to progression (Johnson et al, 2004). A phase III trial
of this regimen (ECOG 4599) has now completed accrual. Given
these results, it will be of particular interest to determine whether a
dual VEGF/EGFR inhibitor will increase the effectiveness of CP
chemotherapy for first-line NSCLC.
CLINICAL EVALUATION OF ZD6474 IN OTHER
TUMOUR TYPES
ZD6474 as monotherapy has been evaluated in a phase II study of
46 patients with previously treated metastatic breast cancer. In this
R
Part B Part  A
ZD6474 300 mg
N
S
C
L
C
 
2
n
d
/
3
r
d
 
l
i
n
e
Gefitinib 250 mg
Gefitinib 250 mg 
n = 80
ZD6474 300 mg 
n = 80
D
i
s
e
a
s
e
 
p
r
o
g
r
e
s
s
i
o
n
 
o
r
 
 
t
o
x
i
c
i
t
y
Figure 3 Gefitinib compared with ZD6474; switch-over study design.
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Figure 4 ZD6474/docetaxel combination study design.
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100 or 300mg (Miller et al, 2004). ZD6474 therapy was generally
well tolerated, with mild diarrhoea and rash being the most
commonly reported adverse events. There were no objective
responses seen in this study. Phase I evaluation of bevacizumab in
patients with advanced cancers, including breast cancer, also
showed no responses (Gordon et al, 2001). A subsequent phase I/II
dose escalation study in previously treated metastatic breast cancer
patients has shown more promising results, with a confirmed
response rate of 6.7% (Cobleigh et al, 2003).
It is possible that the lack of clinical benefit in the ZD6474
study may be due to the advanced, previously treated nature of
the patient group. It is also possible that early-stage tumours have
a greater reliance on VEGF as the principal proangiogenic factor,
while in advanced tumours there may be a degree of redundancy,
with angiogenesis being governed by a wider range of proangio-
genic factors (Relf et al, 1997; Pavlakovic et al, 2001; Kerbel, 2004).
Also, while EGF is an important mediator of normal mammary
gland development and neoplastic transformation, the value of
inhibiting EGF functioning in the treatment of breast cancer
remains uncertain. Further research will elucidate whether certain
tumour types are more or less susceptible to anti-VEGF/EGF
strategies, and breast cancer may prove to be a tumour type that is
difficult to treat with this approach.
Other studies of ZD6474 include small-cell lung cancer (SCLC)
and multiple myeloma (MM). The ongoing SCLC study is
recruiting patients who have experienced a complete or partial
response to induction chemotherapy7radiation therapy. The
primary objective is assessment of time to progression. In
addition, a correlation between outcome or response and tumour
VEGFR expression and microvascular density will be assessed. As
MM is a disease in which angiogenesis is believed to be a relevant
target for therapy, a phase II trial of ZD6474 100mg p.o. daily in
patients with relapsed MM has been conducted. Although ZD6474
therapy was well tolerated in this population, the primary efficacy
end point, objective response as assessed by reduction in M
protein, was not achieved (Kovacs et al, 2004).
CONCLUSIONS
ZD6474 has the potential to exert both direct and indirect
antitumour effects, via inhibition of VEGFR-2 and EGFR tyrosine
kinase activity, respectively. Early clinical evaluation of this
novel agent has demonstrated a promising efficacy and safety
profile and the comprehensive series of ongoing phase II studies
will clarify the value of this approach in the treatment of
solid tumours. Our knowledge of tumour biology suggests that
targeting multiple pathways in tumour growth and development
will be critical, although early clinical experience indicates that
there is still much to be learned about how to optimally combine
these targeted agents with one another and with chemotherapy.
Careful patient selection may be necessary in order to ensure
targeted therapy is administered to those most likely to gain
clinical benefit from this novel therapeutic approach. The
identification of surrogate markers of treatment efficacy will be
key to attaining this goal and is the subject of much ongoing
research.
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Figure 5 Tumour response following two 21-day cycles of ZD6474 (300mgday
 1) plus docetaxel (75mgm
 2 every 21 days) therapy.
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